다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie, v.118, 2019년, pp.109333 -
Hu, Wei (Department of Ultrasound, Renmin Hospital of Wuhan University) , Huang, Xin (Department of Ultrasound, Renmin Hospital of Wuhan University) , Huang, Xingyue (Department of Ultrasound, Renmin Hospital of Wuhan University) , Chen, Wenwei (Department of Ultrasound, Renmin Hospital of Wuhan University) , Hao, Lidan (Department of Ultrasound, Renmin Hospital of Wuhan University) , Chen, Zubing (Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University)
AI-Helper
Abstract T cells edited by chimeric antigen receptors (CAR) have shown great potential in the treatment of tumors, especially malignant blood tumors. However, there remain many obstacles in the CAR-T therapy against solid tumors, such as the expansion of CAR-T cells ex vivo and the exhaustion of CA...
Science Rosenberg 348 6230 62 2015 10.1126/science.aaa4967 Adoptive cell transfer as personalized immunotherapy for human cancer
Nat. Med. Fry 24 1 20 2018 10.1038/nm.4441 CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
N. Engl. J. Med. Grupp 368 16 1509 2013 10.1056/NEJMoa1215134 Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
Blood Kochenderfer 116 20 4099 2010 10.1182/blood-2010-04-281931 Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
Cell Lim 168 4 724 2017 10.1016/j.cell.2017.01.016 The principles of engineering immune cells to treat cancer
Trends Immunol. Srivastava 36 8 494 2015 10.1016/j.it.2015.06.004 Engineering CAR-T cells: design concepts
Int. J. Cancer Schubert 142 9 1738 2018 10.1002/ijc.31147 Chimeric antigen receptor transduced T cells: tuning up for the next generation
Cancers (Basel) Sridhar 9 7 2017 10.3390/cancers9070092 Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy
Leukemia Collinson-Pautz 2019 10.1038/s41375-019-0417-9 Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
Cancer Lett. Sengupta 433 131 2018 10.1016/j.canlet.2018.06.035 Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells
Am. Soc. Clin. Oncol. Educ. Book Yeku 37 193 2017 10.1200/EDBK_180328 Adoptive T-cell therapy for solid tumors
Blood Guedan 124 7 1070 2014 10.1182/blood-2013-10-535245 ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
JCI Insight Guedan 3 1 2018 10.1172/jci.insight.96976 Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Cancer Immunol. Immunother. Chen 66 4 475 2017 10.1007/s00262-016-1949-8 Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma
Hepatobiliary Pancreat. Dis. Int. Chen 17 4 301 2018 10.1016/j.hbpd.2018.05.005 Chimeric antigen receptor-engineered T-cell therapy for liver cancer
Front. Immunol. Jiang 7 690 2016 Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma
Protein Cell Ma 9 7 664 2018 10.1007/s13238-017-0489-0 Redirecting T cells to glypican-3 with 28.41BB.zeta and 28.zeta-41BBL CARs for hepatocellular carcinoma treatment
Cancer Res. Metzger 76 13 3684 2016 10.1158/0008-5472.CAN-15-3412 ICOS promotes the function of CD4+ effector T cells during anti-OX40-mediated tumor rejection
Cancer Immunol. Res. Ng Tang 1 4 229 2013 10.1158/2326-6066.CIR-13-0020 Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy
Cancer Immunol. Immunother. Blaeschke 67 7 1053 2018 10.1007/s00262-018-2155-7 Induction of a central memory and stem cell memory phenotype in functionally active CD4(+) and CD8(+) CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19(+) acute lymphoblastic leukemia
Cancers (Basel) Golubovskaya 8 3 2016 10.3390/cancers8030036 Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy
Cancer Immunol. Res. Harao 5 6 439 2017 10.1158/2326-6066.CIR-16-0364 4-1BB-enhanced expansion of CD8(+) TIL from triple-negative breast cancer unveils mutation-specific CD8(+) T cells
Clin. Cancer Res. Sakellariou-Thompson 23 23 7263 2017 10.1158/1078-0432.CCR-17-0831 4-1BB agonist focuses CD8(+) tumor-infiltrating T-cell growth into a distinct repertoire capable of tumor recognition in pancreatic cancer
Sci. Transl. Med. Turtle 8 355 2016 10.1126/scitranslmed.aaf8621 Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
JCI Insight Wang 3 10 2018 10.1172/jci.insight.99048 Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
Nat. Commun. Chin 9 1 4679 2018 10.1038/s41467-018-07136-7 Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
J. Hematol. Oncol. Molckovsky 1 20 2008 10.1186/1756-8722-1-20 First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.